Neogenomics Inc (NASDAQ:NEO) price on Thursday, April 10, fall -2.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.90.
A look at the stock’s price movement, the close in the last trading session was $9.12, moving within a range at $8.5103 and $9.13. The beta value (5-Year monthly) was 1.406. Turning to its 52-week performance, $19.11 and $8.05 were the 52-week high and 52-week low respectively. Overall, NEO moved -13.00% over the past month.
Neogenomics Inc’s market cap currently stands at around $1.14 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-17.
Analysts have a consensus estimate of 171.32M for the company’s revenue for the quarter, with a low and high estimate of 169.22M and 172.9M respectively. The average forecast suggests up to a 9.65% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 738.38M, representing a 11.78% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NEO is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 7 recommend NEO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NEO’s current price about -5.55% and -18.39% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.20, while 7-day volatility ratio is 12.43% and 7.24% in the 30-day chart. Further, Neogenomics Inc (NEO) has a beta value of 1.55, and an average true range (ATR) of 0.78. Analysts have given the company’s stock an average 52-week price target of $18, forecast between a low of $18 and high of $18. Looking at the price targets, the low is -102.25% off current price level while to achieve the yearly target high, price needs to move -102.25%. Nonetheless, investors will most likely welcome a -102.25% jump to $18 which is the analysts’ median price.
If we refocus on Neogenomics Inc (NASDAQ:NEO), historical trading data shows that trading volumes averaged 2.04 over the past 10 days and 1.45 million over the past 3 months. The company’s latest data on shares outstanding shows there are 128.15 million shares.
The 1.20% of Neogenomics Inc’s shares are in the hands of company insiders while institutional holders own 101.35% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.22 million on 2025-03-14, giving us a short ratio of 2.58. The data shows that as of 2025-03-14 short interest in Neogenomics Inc (NEO) stood at 456.00000000000006 of shares outstanding, with shares short rising to 3.43 million registered in 2025-02-14. Current price change has pushed the stock -46.00% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NEO stock continues to rise going into the next quarter.
